TABLE 3.
Reported adverse effects by age stratification and dose administration among the study population
| Adverse effect | Total N | Age | Chi square | |
|---|---|---|---|---|
| 18‐44 years (%) | 45+ years (%) | |||
| Pain at injection site | 1316 | 840 (63.83) | 476 (36.17) | <0.001 |
| Redness at injection site | 182 | 97 (53.30) | 85 (46.70) | 0.016 |
| Swelling at injection site | 208 | 138 (66.35) | 70 (33.65) | 0.115 |
| Fever | 529 | 369 (69.75) | 160 (30.25) | <0.001 |
| Chills | 703 | 491(69.84) | 212 (30.16) | <0.001 |
| Fatigue | 1080 | 715 (66.20) | 365 (33.80) | <0.001 |
| Muscle pain | 841 | 563 (66.94) | 278 (33.06) | <0.001 |
| Joint pain | 498 | 325 (65.26) | 173 (34.74) | 0.031 |
| Headache | 655 | 440 (67.18) | 215 (32.82) | <0.001 |
| Vomiting | 34 | 26 (76.47) | 8 (23.53) | 0.068 |
| Diarrhoea | 81 | 44 (54.32) | 37 (45.68) | 0.177 |
| Adverse effect | Total N | Dose | Chi square | ||
|---|---|---|---|---|---|
| First dose (%) | Second dose (%) | First and second doses (%) | |||
| Pain at injection site | 1294 | 430 (33.23) | 219 (16.92) | 645 (49.85) | <0.001 |
| Redness at injection site | 177 | 73 (41.24) | 49 (27.68) | 55 (31.07) | <0.001 |
| Swelling at injection site | 118 | 41 (34.75) | 34 (28.81) | 43 (36.44) | <0.001 |
| Fever | 524 | 52 (9.92) | 419 (79.96) | 53 (10.11) | <0.001 |
| Chills | 696 | 78 (11.21) | 547 (78.59) | 71 (10.20) | <0.001 |
| Fatigue | 1060 | 188 (17.74) | 641 (60.47) | 231 (21.79) | <0.001 |
| Muscle pain | 712 | 106 (14.89) | 434 (60.96) | 172 (24.16) | <0.001 |
| Joint pain | 491 | 77 (15.68) | 360 (73.32) | 54 (11.00) | <0.001 |
| Headache | 639 | 115 (18.00) | 384 (60.09) | 140 (21.91) | <0.001 |
| Vomiting | 31 | 6 (19.35) | 21 (67.74) | 4 (12.90) | 0.07 |
| Diarrhoea | 80 | 14 (17.50) | 55 (68.75) | 11 (13.75) | <0.001 |